On Friday, Kosmos Energy Ltd (NYSE:KOS)’s shares declined -1.27% to $8.57.
Kosmos Energy Ltd. (KOS) declared an amendment and restatement of its corporate revolving credit facility. Three noteworthy changes have been made:
Borrowing capacity has been raised to $400 million, up from $300 million
Date of maturity has been extended by three years to November 2018, and
Commitment fees have been lowered to 30% of the margin.
Combined with its $1.5 billion reserves-based lending facility, Kosmos now has secured debt facilities totaling $1.9 billion, of which only $300 million was drawn as of June 1, 2015.
Kosmos Energy Ltd. explores for and produces oil and gas in Africa, Europe, and South America. Its asset portfolio comprises production and other development projects in offshore Ghana, in addition to exploration licenses with hydrocarbon potential in offshore Ireland, Mauritania, Morocco, Senegal, and Suriname. The company was founded in 2003 and is based in Hamilton, Bermuda.
Baidu Inc (ADR) (NASDAQ:BIDU)’s shares dropped -2.02% to $203.36.
Baidu Inc (ADR) (BIDU) declared the pricing of its public offering of US$1.25 billion aggregate principal amount of its notes. The public offering comprises of US$750 million of 3.000% notes due 2020 and US$500 million of 4.125% notes due 2025. The notes have been registered under the U.S. Securities Act of 1933, as amended, and are predictable to be listed on the Singapore Exchange Securities Trading Limited.
The Company anticipates to receive net proceeds from the offering of about US$1.24 billion, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes.
The joint bookrunners of the offering are Goldman Sachs (Asia) L.L.C. and J.P. Morgan Securities LLC.
Baidu, Inc. provides Internet search services in China and internationally. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, counting Web pages, news, images, documents, and multimedia files through links offered on its Website; and international products and services to users in other countries.
At the end of Friday’s trade, Derma Sciences Inc (NASDAQ:DSCI)‘s shares surged 0.85% to $7.09.
Derma Sciences, Inc. (DSCI), a tissue regeneration company focused on advanced wound and burn care, declares the publication of a review of the current clinical development program for aclerastide (DSC127), a patented peptide analog of angiotensin, as a potential treatment for the closure of diabetic foot ulcers (DFUs) in an article titled, “NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers,” in the peer-reviewed journal, Advances in Wound Care. The full article can be accessed here or on the Company’s website at www.dermasciences.com.
Aclerastide, also known as NorLeu3-A(1-7), is an analog of the active member of the RAS, A(1-7). The peptide accelerates and normalizes the healing/closure of dermal injuries in multiple animal models. In Phase I and II human clinical studies, aclerastide raised the incidence of full closure of DFUs.
Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. Its Advanced Wound Care segment offers MEDIHONEY dressings for managing non-chronic and hard-to-heal wounds, counting chronic ulcers, burns, and post-operative wounds; TCC-EZ system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair, reconstruction, and replacement; and AMNIOMATRIX that is used as a wound covering in the treatment of localized tissue defects. This segment also provides XTRASORB dressings, which convert fluid within the dressings to a gel and lock the exudates into the dressings; BIOGUARD dressings for prophylactic use in the prevention of hospital or community attained infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products.
Diodes Incorporated (NASDAQ:DIOD), ended its Friday’s trading session with -2.60% loss, and closed at $24.74.
Diodes Incorporated ( DIOD), a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets, today introduced the NIS5135. Designed to enhance system reliability against shutdown and catastrophic failures, this resettable electronic fuse is well-suited for plug and play applications in consumer applications including hard disc and solid state drives, printers, and set-top boxes. By allowing the product to recover, this e-fuse helps reduce unnecessary field returns.
Operating over a wide 3.1V to 18V input voltage range and rated at 3.6A, the NIS5135 integrates an NMOS power device with a low 30mΩ RDS(ON) for reduced power loss. It also features an internal current limit that avoids the voltage drop normally incurred by an external sense resistor in the load path. An over-voltage circuit limits the output voltage without shutting the device down, while downstream components are further protected from damage or premature failure by under-voltage lockout (UVLO) and thermal shutdown circuits, with latching (NIS5135MN1) or auto-retry (NIS5135MN2) options.
Diodes Incorporated, together with its auxiliaries, designs, manufactures, and supplies application-specific standard products in the discrete, logic, and analog semiconductor markets primarily in Asia, North America, and Europe. The company principally focusses on low pin count semiconductor devices with one or more active and/or passive components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
